Lawrence G. Hamann

8.5k total citations · 3 hit papers
64 papers, 4.2k citations indexed

About

Lawrence G. Hamann is a scholar working on Organic Chemistry, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Lawrence G. Hamann has authored 64 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Organic Chemistry, 24 papers in Molecular Biology and 23 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Lawrence G. Hamann's work include Estrogen and related hormone effects (14 papers), Peptidase Inhibition and Analysis (11 papers) and Diabetes Treatment and Management (9 papers). Lawrence G. Hamann is often cited by papers focused on Estrogen and related hormone effects (14 papers), Peptidase Inhibition and Analysis (11 papers) and Diabetes Treatment and Management (9 papers). Lawrence G. Hamann collaborates with scholars based in United States, Switzerland and Germany. Lawrence G. Hamann's co-authors include Philip P. Chamberlain, Diane L. Crombie, Nicholas A. Meanwell, Makonen Belema, Peter J. Davies, Ranjan Mukherjee, James R. Paterniti, Alex M. Nadzan, Lily Jow and Rosemary M. Cesario and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

Lawrence G. Hamann

63 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

2010 689 citations Lawrence G. Hamann et al. profile →
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

1997 515 citations Lawrence G. Hamann et al. profile →
Development of targeted protein degradation therapeutics

2019 344 citations Lawrence G. Hamann et al. profile →

Peers

Countries citing papers authored by Lawrence G. Hamann

Since Specialization

Citations

This map shows the geographic impact of Lawrence G. Hamann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence G. Hamann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence G. Hamann more than expected).

Fields of papers citing papers by Lawrence G. Hamann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence G. Hamann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence G. Hamann. The network helps show where Lawrence G. Hamann may publish in the future.

Co-authorship network of co-authors of Lawrence G. Hamann

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence G. Hamann. A scholar is included among the top collaborators of Lawrence G. Hamann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence G. Hamann. Lawrence G. Hamann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Context-dependent translation inhibition as a cancer therapeutic modality 2026 ·Nature Communications ·(unknown), Paul Sauer, Mikael Holm, (unknown), Lucas Ferguson, (unknown), (unknown), Jongmin Sim, (unknown), (unknown), (unknown), David Gygi, (unknown), (unknown), Lawrence G. Hamann, Anthony P. Schuller	0
2	Intermolecular Crossed [2 + 2] Cycloaddition Promoted by Visible-Light Triplet Photosensitization: Expedient Access to Polysubstituted 2-Oxaspiro[3.3]heptanes 2021 ·Journal of the American Chemical Society ·Philip R. D. Murray, (unknown), Geraint H. M. Davies, Farid W. van der Mei, (unknown), Jacob T. Edwards, (unknown), J. Michael Ellis, Lawrence G. Hamann, Fedor Romanov‐Michailidis, Robert R. Knowles	63
3	Quaternary Charge-Transfer Complex Enables Photoenzymatic Intermolecular Hydroalkylation of Olefins 2020 ·Journal of the American Chemical Society ·Claire G. Page, Simon J. Cooper, (unknown), Daniel G. Oblinsky, Kyle F. Biegasiewicz, (unknown), (unknown), J. Michael Ellis, Lawrence G. Hamann, (unknown), Kevin M. Oberg, Gregory D. Scholes, Todd K. Hyster	110
4	Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO) 2020 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Linhong Deng, Evan Cohick, (unknown), (unknown), (unknown), (unknown), Tyler Harrison, Julien P. N. Papillon, Natalie A. Dales, Lawrence G. Hamann, (unknown), Jean B. Regard, Jovita Marcinkeviciene, (unknown), Andrew W. Patterson	9
5	Expedient access to saturated nitrogen heterocycles by photoredox cyclization of imino-tethered dihydropyridines 2019 ·Chemical Science ·Noah B. Bissonnette, J. Michael Ellis, Lawrence G. Hamann, Fedor Romanov‐Michailidis	22
6	Late-stage C–H functionalization of complex alkaloids and drug molecules via intermolecular rhodium-carbenoid insertion 2015 ·Nature Communications ·(unknown), Lawrence G. Hamann, Huw M. L. Davies, Rohan E. J. Beckwith	116
7	2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication 2014 ·Bioorganic & Medicinal Chemistry Letters ·Erin P. Keaney, Michael Connolly, Markus Dobler, Rajeshri G. Karki, Ayako Honda, (unknown), (unknown), (unknown), (unknown), Prakash Raman, Lawrence G. Hamann, Brigitte Wiedmann, Matthew J. LaMarche	23
8	Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Guohua Zhao, Chet Kwon, Aiying Wang, James G. Robertson, Jovita Marcinkeviciene, Rex A. Parker, Mark Kirby, Lawrence G. Hamann	11
9	Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor 2012 ·BMC Pharmacology ·Aiying Wang, Charles R. Dorso, Lisa M. Kopcho, Gregory Locke, Robert A. Langish, Eric B. Harstad, Petia Shipkova, Jovita Marcinkeviciene, Lawrence G. Hamann, Mark Kirby	49
10	7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site 2011 ·Bioorganic & Medicinal Chemistry Letters ·Wei Wang, Pratik Devasthale, Aiying Wang, (unknown), (unknown), Nathan Morgan, Michael Cap, Aberra Fura, Herbert E. Klei, Kevin Kish, Carolyn A. Weigelt, Lucy Sun, Paul Lévesque, Yixin Li, Robert Zahler, Mark Kirby, Lawrence G. Hamann	15
11	Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation 2008 ·Protein Science ·William J. Metzler, Joseph Yanchunas, Carolyn A. Weigelt, Kevin Kish, Herbert E. Klei, Dianlin Xie, Yaqun Zhang, Martin J. Corbett, James Tamura, Bin He, Lawrence G. Hamann, Mark Kirby, Jovita Marcinkeviciene	103
12	Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency 2007 ·Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics ·(unknown), Michael Flynn, (unknown), Mary Ellen K. Salyan, Donna L. Pedicord, Rajasree Golla, Zhengping Ma, Haixia Wang, Ramakrishna Seethala, Shung Wu, James J. Li, Akbar Nayeem, Cynthia A. Gates, Lawrence G. Hamann, David A. Gordon, Yuval Blat	16
13	Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats 2006 ·Endocrinology ·Jacek Ostrowski, (unknown), John A. Lupisella, (unknown), Blake C. Beehler, Stanley R. Krystek, Yingzhi Bi, Chong‐Qing Sun, Ramakrishna Seethala, Rajasree Golla, Paul G. Sleph, Aberra Fura, Yongmi An, Kevin Kish, John S. Sack, Kasim A. Mookhtiar, Gary J. Grover, Lawrence G. Hamann	99
14	Structure–activity relationships and sub-type selectivity in an oxabicyclic estrogen receptor α/β agonist scaffold 2005 ·Bioorganic & Medicinal Chemistry Letters ·Lawrence G. Hamann, Jeffrey H. Meyer, (unknown), Keith B. Marschke, Francisco J. López, Elizabeth A. Allegretto, Donald S. Karanewsky	36
15	Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) 2005 ·Archives of Biochemistry and Biophysics ·Young B. Kim, Lisa M. Kopcho, Mark Kirby, Lawrence G. Hamann, Carolyn A. Weigelt, William J. Metzler, Jovita Marcinkeviciene	62
16	N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase 2004 ·Bioorganic & Medicinal Chemistry Letters ·Karnail S. Atwal, Saleem Ahmad, Charles Z. Ding, Philip D. Stein, John Lloyd, Lawrence G. Hamann, David W. Green, (unknown), (unknown), W. Lynn Rogers, (unknown), Arthur V. Miller, (unknown), (unknown), Ling Li, K. J. Yost, (unknown), Cort S. Madsen	12
17	Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinolines 2000 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Lawrence G. Hamann, (unknown), James P. Edwards, Keith B. Marschke, Todd K. Jones	13
18	Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one 1999 ·Bioorganic & Medicinal Chemistry Letters ·James P. Edwards, Robert I. Higuchi, David T. Winn, (unknown), Thomas R. Caferro, Lawrence G. Hamann, (unknown), Keith B. Marschke, Mark E. Goldman, Todd K. Jones	42
19	Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines 1998 ·Bioorganic & Medicinal Chemistry Letters ·Lawrence G. Hamann, David T. Winn, (unknown), Christopher M. Tegley, Sarah J. West, Luc J. Farmer, Zhi Lin, James P. Edwards, Keith B. Marschke, Dale E. Mais, Mark E. Goldman, Todd K. Jones	19
20	Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists 1995 ·Annals of the New York Academy of Sciences ·Lawrence G. Hamann, Luc J. Farmer, Michael G. Johnson, Mark E. Goldman, Dale E. Mais, (unknown), Steven L. Bender, Todd K. Jones	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact